Predictive chemosensitivity testing

Cancer Chemosensitivity Testing: Review

Since chemotherapy started in 1940s, chemosensitivity testing has been both a very attractive field and one fraught with potential pitfalls. Many methods were developed and brought initial promises, yet later ending in disappointment and were eliminated. For example, in the 1970s clonogenic assay was generally believed to be the best testing method for predicting clinical outcome. However, tech...

Challenges of chemosensitivity testing.

One of the major goals in cancer therapeutics is to increase efficacy and reduce toxicity by tailoring therapy to individual patients. It is well known that tumors and patients are heterogeneous, and with every therapeutic approach, whether immunotherapy, chemotherapy, or antivascular strategy, patient response can be extremely variable, ranging from progression to complete responses. Understan...

Chemosensitivity testing: another chapter.

In vitro chemosensitivity testing of anticancer agents for patient treatment has evolved gradually since the time of our report in 1978 (7) on the use of a human tumor cloning or tumor stem cell assay for this purpose. Although some technical problems remain, definite improvement has been seen in the frequency of in vitro sensitivity results with several assay systems {2-4). One important quest...

Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri.

BACKGROUND Up-front temozolomide (TMZ) has been recently proposed as a treatment for gliomatosis cerebri (GC), but no predictive or prognostic markers have been identified so far. Because 1p19q codeletion and methylguanine methyl transferase promoter (MGMTP) methylation have been correlated with chemosensitivity of gliomas, their value was investigated in a cohort of patients with GC treated wi...

Predictive Genetic Testing